Eribulin in 'field practice': an overview of the Italian experience.

Abstract

Future OncologyVol. 11, No. 15s ForewordFree AccessEribulin in ‘field practice’: an overview of the Italian experienceThis article is corrected byCorrigendumSandro BarniSandro Barni*Author for correspondence: E-mail Address: sandro.barni@ospedale.treviglio.bg.it Medical Oncology, Azienda Ospedaliera, Treviglio-Caravaggio, Treviglio (BG) ItalySearch for more papers by this authorPublished Online:3 Aug 2015https://doi.org/10.2217/fon.15.157AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: breast cancercase studyerbulin mesylateBreast cancer remains the most common oncological disease in women. Although the diagnostic and therapeutic advantages achieved in recent years have led to a decrease in the incidence of breast cancer-related deaths, metastatic breast cancer is still associated with an overall poor prognosis [1,2].The therapy of metastatic breast cancer mainly focuses on control of symptoms and minimization of toxicities, with the aim of extending patients’ survival and maintaining quality of life. A number of agents, with different mechanisms of action, are available for the treatment of this complex disease.In particular, eribulin mesylate is a synthetic analog of halichondrin B, a natural product isolated from a marine sponge. Eribulin induces irreversible mitotic block and apoptosis by inhibiting microtubule polymerization [3]. The efficacy of this agent has been shown in the Phase III EMBRACE trial, which at present is the only trial in heavily treated breast cancer showing an advantage in overall survival [4]. Following the results of this trial, eribulin has been approved for the treatment of patients with metastatic breast cancer after anthracyclines and taxanes treatment.The reporting of well-conducted field-practice experiences has a mounting importance in the oncology setting [5]. Indeed, observational studies and peculiar case reports can complement the results of clinical trials, which are often conducted in selected populations under stringent treatment and follow-up conditions.The present supplement collects, for the first time to our knowledge, a number of Italian field-practice experiences with eribulin in the treatment of metastatic breast cancer. In particular, the case report by Borgonovo et al. [6] describes the management of a patient who experienced a time to progression of several months with eribulin after three lines of chemotherapy and two lines of hormonal therapy. Casanova et al. [7] in their manuscript comment on the management of a HER2+ patient who maintained eribulin treatment for a total of nine cycles. The prolonged benefit with eribulin is also addressed and discussed by Iorfida and Mazza [8]. Gubbiotti et al. present a different topic, that is, the efficacy of eribulin on retinal and brain metastases [9], while Leo et al. discuss the use of this molecule in a very heavily pretreated patient with multiple bone metastases [10]. Finally, Martella et al. present the experience of a single institution with eribulin [11].We believe that this supplement does add much to the current bulk of knowledge on the efficacy and safety of eribulin. We hope that the reported experiences will be the starting point for a deeper investigation and use of eribulin in clinical practice.DisclaimerThe supporting company was not offered the opportunity to revise the paper and had no role in the decision to submit.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, on behalf of Content Ed Net, and Ambra Corti. This assistance was funded by Eisai.References1 Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Center J. Clin. 61(2), 69–90 (2011).Crossref, Medline, Google Scholar2 Dawood S, Broglio K, Gonzalez-Angulo AM et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J. Clin. Oncol. 26(30), 4891–4898 (2008).Crossref, Medline, Google Scholar3 Towle MJ, Salvato KA, Wels BF et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 71, 496–505 (2011).Crossref, Medline, CAS, Google Scholar4 Cortés J, O'Shaughnessy J, Loesch J et al. Eribulin monotherapy versus treatment at physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase III open-label randomized study. Lancet 377, 914–923 (2011).Crossref, Medline, CAS, Google Scholar5 Rizzo M, Cartenì G, Pappagallo G. We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC. Future Oncol. 10(12), 1893–1896 (2014).Link, CAS, Google Scholar6 Borgonovo K, Petrelli F, Cabiddu M et al. Long response to eribulin in breast cancer: a case report. Future Oncol. 11(Suppl. 15), 3–8 (2015).Link, CAS, Google Scholar7 Casanova C, Verlicchi A, Mazza V, Dazzi C. Benefit of eribulin in a patient with HER2+ breast cancer who progressed after trastuzumab and lapatinib: a case report. Future Oncol. 11(Suppl. 15), 9–15 (2015).Link, CAS, Google Scholar8 Iorfida M, Mazza M. Long-lasting control with eribulin in a taxane ­pretreated metastatic breast cancer patient. Future Oncol. 11(Suppl. 15), 23–26 (2015).Link, CAS, Google Scholar9 Gubbiotti M, Pistilli B, Tudini M et al. Retinal metastasis regression with eribulinin a heavily pretreated breast cancer patient. Future Oncol. 11(Suppl. 15), 17–22 (2015).Link, CAS, Google Scholar10 Leo L, Caputo F, Di Sarno A et al. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report. Future Oncol. 11(Suppl. 15), 27–30 (2015).Link, CAS, Google Scholar11 Martella D, Bacci C, Giordano C et al. Eribulin mesylate in advanced breast c­ancer: r­etrospective review of a single institute e­xperience. Future Oncol. 11(Suppl. 15), 31–36 (2015).Link, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByEfficacy and safety of eribulin in taxane-refractory patients in the ‘real world’Vito Lorusso, Saverio Cinieri, Agnese Latorre, Luca Porcu, Lucia Del Mastro, Fabio Puglisi & Sandro Barni24 February 2017 | Future Oncology, Vol. 13, No. 11Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myelomaConcetta Conticello, Marina Parisi, Alessandra Romano, Valeria Calafiore, Flavia Ancora, Alessia La Fauci, Maria Letizia Consoli & Francesco Di Raimondo24 January 2017 | Future Oncology, Vol. 13, No. 5sPomalidomide in heavily pretreated refractory multiple myeloma: a case reportAngelo Palmas, Giovanna Piras, Antonella Uras, Rosanna Asproni, Marco Murineddu, Maria Monne, Roberta Stradoni & Giancarlo Latte24 January 2017 | Future Oncology, Vol. 13, No. 5sPomalidomide: when expectations are understatedFrancesco Di Raimondo & Concetta Conticello24 January 2017 | Future Oncology, Vol. 13, No. 5sRelated articlesCorrigendum11 Sep 2015Future Oncology Vol. 11, No. 15s eToC Sign up Follow us on social media for the latest updates Metrics History Published online 3 August 2015 Published in print August 2015 Information© Future Medicine LtdKeywordsbreast cancercase studyerbulin mesylateDisclaimerThe supporting company was not offered the opportunity to revise the paper and had no role in the decision to submit.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, on behalf of Content Ed Net, and Ambra Corti. This assistance was funded by Eisai.PDF download